nPhase, a clinical research technology company, has launched nPhase.ai, the life sciences industry’s first enterprise platform for end-to-end clinical data management.
The company also introduces nPhase.ai SCE (Statistical Computing Environment). An AI-native platform built on Clinical Data Interchange Standards Consortium (CDISC) standards, the governed platform transforms raw clinical trial data into submission-ready outputs at least 4x faster with 80% fewer resources.
Clinical trial data has outgrown existing systems both in volume and complexity. A recent Tufts CSDD analysis found the average phase 3 protocol now generates nearly six million data points. Most of that volume arrives from unstructured data systems that were never designed to interoperate, leaving sponsors with data that is difficult to reuse or be leveraged by AI.
nPhase.ai SCE automatically converts raw study data into the regulatory artifacts required for submission through one, governed, and traceable pipeline. It compresses a process that typically takes four or more months to weeks. Every week gained between last-patient-last-visit and submission not only accelerates treatments to patients but also gives sponsors additional market exclusivity.
